Search in
Value | Source |
---|---|
[1,2,3,7,8,8a-Hexahydro-8-[2-(tetrahydro-4-hydroxy-6-oxo-2-pyranyl)-ethyl]-3,7-dimethyl-1-naphthyl]-2-methylbutyrat
|
Value | Source |
---|---|
Lovastatin
| |
(3R,5R)-7-[(1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-Hexahydro-2,6-dimethyl-8-[(S)-2-methylbutyryloxy]-1-naphthyl]-3-hydroxyheptan-5-olide
| |
(1S,3S,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthyl (S)-2-methyllbutyrate
| |
1,2,6,7,8,8a-Hexahydro-beta,delta-dihydroxy-2,6-dimethyl-8-(2-methyl-1-oxobutoxy)-1-naphthalenheptansäure-delta-lacton
| |
[1S-[1alpha(R*),3alpha,7beta,8beta(2S*,4S*),8alphabeta]]-2-Methyl-butansäure-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenylester
| |
[1,2,3,7,8,8a-Hexahydro-8-[2-(tetrahydro-4-hydroxy-6-oxo-2-pyranyl)-ethyl]-3,7-dimethyl-1-naphthyl]-2-methylbutyrat
| |
Monakolin K
| |
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate
| |
Butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, (2S)-
|
Value | Source |
---|---|
Artein
| |
Lestatin
| |
Lovacol
| |
Lovatec
| |
Mevacor
| |
Mevinolin
| |
MK-803
| |
Monacolin K
| |
Nergadan
| |
Reducol
| |
Sivlor
| |
Taucor
| |
Tecnolip
|
Value | Source |
---|---|
Butanoic acid, 2-methyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydr oxy- 6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (1S-(1-alpha-(R*),3-alpha,7-beta, 8-beta-(2S*,4S*),8a-beta))-
| |
Butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, (2S)-
|
Value | Source |
---|---|
Ловастин
|
Value | Source |
---|---|
[1S-[1-α-(R*),3-α,7-β,8-β-(2S*,4S*),8a-β]]-1,2,3,7,8,8a-六氢-3,7-二甲基-8-[2-(四氢-4-羟基 -6-氧-2H-吡喃-2-基)乙基]-1-萘基-2-甲基丁酸
| |
洛伐他汀或罗瓦停
|
Value | Source |
---|---|
75330-75-5
|
Value | Source |
---|---|
616-212-7
|
Value | Source |
---|---|
0037738
|
1203 | IGS-Betreiberzentrum im LANUV NRW |
2313 | Verordnung über die Verschreibungspflicht von Arzneimitteln (Arzneimittelverschreibungsverordnung, AMVV), 10/2022 |
2344 | Allg. VwV über die Anerkennung und Nutzungsgenehmigung von natürlichem Mineralwasser 3/2001 |
2411 | Neufassung der Ersten Allgemeinen Verwaltungsvorschrift zum Bundes-Immissionsschutzgesetz (Technische Anleitung zur Reinhaltung der Luft - TA Luft) |
2455 | Allgemeine VwV zur Ermittlung von Packungsgrößen nach § 5 PackungsV 9/2023 |
2470 | M. Negwer, Organic-chemical drugs and their synonyms, Akademie-Verlag, 7. Auflage, 1994 |
3130 | DHL Einfuhr- und Zollvorschriften 2009 |
3807 | BVL/BfArM Gemeinsame Stellungnahmen - 2/2016 |
3967 | Arbeidstilsynet, Tiltaks- og grenseverdier, Forskrift nr.704 (NO), 7/2022 |
4023 | ECHA (European Chemicals Agency) Substance Information - Infocards, 2/2016 |
4165 | List of Hazardous Chemicals (CN), 2015 |
4238 | Inventory of Existing Chemical Substance of China (Version 2013), zul.geänd. 10/2023 |
4271 | REACH Vorregistrierung 3/2009 |
4420 | New Zealand Inventory of Chemical Substances, 10/2015 |
4525 | REACH Registry, -8/2019 |
4580 | GN 2.2.5.3532-18 Predel'no dopustimyye kontsentratsii (PDK) vrednykh veshchestv v vozdukhe rabochey zony, 2/2018, veröffentlicht in: Sanitarniyye pravila i normy SANPIN 1.2.3685-21 Gigienycheskiye normativy i trebovaniya k obespecheniyu bezoprasnosti i (ILI) bezvrednosti dyla cheloveka faktorov sredy obitanya, 3/2021 |
8091 | LANUV Identbearbeitung |
8095 | LANUV Literaturrecherche -2018 |